An experienced team — in pursuit of scientific excellence.

Ashok is a serial entrepreneur and investor focused on enterprise IT, and the intersection of computer science and life sciences. Most recently he founded two medical related companies: CAPP Medical, a liquid biopsy company for cancer diagnosis that he sold to Roche Diagnostics, and CiberMed which focuses on biomarker discovery. Previously he founded Xsigo, a provider of advanced data center connectivity, which he sold to Oracle. Prior to Xsigo, Ashok was one of the early leaders of Juniper Networks where he helped develop many of the products that power today’s internet, and which was one of the largest venture investment returns of all time. Ashok has also been an investor in a number of innovative companies like GoEuro, Reflektion, OttoQ, Veradocs, Falcon Systems, Robin Systems, and Scoredata amongst others.

Aki is a data science / bioinformatics expert with 20 years of experience in the biotechnology industry. She currently leads Bioinformatics, Software/IT, and Operations including Client Relations and Customer Support. Prior to CiberMed, Aki served as Director of Informatics at Quantum Biosystems, Director of Bioinformatics at Complete Genomics, and at Roche Diagnostics with increasing responsibilities. She holds a Master of Engineering from University of Tokyo.

Aaron is a co-founder of CiberMed and an Assistant Professor of Biomedical Data Science at Stanford. His research program focuses on developing innovative data science tools to study the phenotypic diversity, differentiation hierarchies, and clinical significance of tumor cells and their surrounding microenvironments. As part of this effort, Aaron has made significant contributions to computational biology, including CIBERSORT/x, which is widely used to determine cellular composition from bulk tissue genomic profiles; EcoTyper to decipher cell states and multicellular ecosystems at massive scale; CytoTRACE for inferring differentiation states from single-cell expression data; and CytoSPACE for enhancing the spatial resolution and gene coverage of spatial transcriptomics data. Key results are further explored experimentally, with the ultimate goal of translating promising findings into next-generation diagnostics and anti-cancer therapies.

Ash has a significant history of research and accomplishments in cancer genomics, beginning with the original development of microarray gene expression profiling for cancer classification starting with lymphomas, and advancing to multiple tumor types. His group helped develop techniques for ultra-sensitive and non-invasive detection of tumor-derived cell-free DNA (CAPP-Seq), and for computational deconvolution of gene expression data for deciphering cellular heterogeneity in tumors including immune infiltration (CIBERSORT). His translational research effort is focused on attaining a more sophisticated understanding of the initiation, maintenance, and progression of tumors and their response to therapy toward improving current treatment strategies. In this effort, his group employs tools from functional genomics, computational biology, molecular genetics, and mouse models. Clinically, he is a practicing medical oncologist specializing in the care of patients with lymphoma, including diffuse large B-cell lymphomas (DLBCL), with his clinical research is focused on diagnostic, prognostic, and predictive markers and on translating discoveries from the laboratory to the clinic using cutting tools in data science.

Max Diehn is a co-founder of CiberMed and a Professor of Radiation Oncology at Stanford. He is a physician scientist with an active clinical practice focused on lung cancer. His research group co-developed techniques for ultra-sensitive and non-invasive detection of circulating tumor DNA and contributed to the development of CIBERSORT. His research efforts are focused on developing novel approaches for personalizing treatment of cancer patients.